Acquired angioedema secondary to C1 esterase inhibitor deficiency (AAE-C1-INH) requires a tailored long-term management approach. When attack frequency remains below 2 episodes per week, a specific first-line strategy is indicated.
This protocol applies to patients with a confirmed diagnosis of AAE-C1-INH who are experiencing fewer than 2 angioedema attacks per week.
The first-line approach for this patient population involves an antifibrinolytic agent. The complete structured regimen — including agent selection, dosing, and monitoring parameters — is available in the full protocol.